Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The I HART CGM study showed that real-time continuous glucose monitoring (RT-CGM) has greater beneficial impact on hypoglycemia than intermittent flash glucose monitoring (flash) in adults with type 1 diabetes (T1D) at high risk. The impact of continuing RT-CGM or switching from flash to RT-CGM for another 8 weeks was then evaluated. METHODS: Prospective randomized parallel group study with an extension phase. After a 2-week run-in with blinded CGM, participants were randomized to either RT-CGM or flash for 8 weeks. All participants were then given the option to continue with RT-CGM for another 8 weeks. Glycemic outcomes at 8 weeks are compared with the 16-week endpoint. RESULTS: Forty adults with T1D on intensified multiple daily insulin injections and with impaired awareness of hypoglycemia or a recent episode of severe hypoglycemia were included (40% female, median [IQR] age 49.5 [37.5-63.5] years, diabetes duration 30.0 [21.0-36.5] years, HbA1c 56 [48-63] mmol/mol, and Gold Score 5 [4-5]), of whom 36 completed the final 16-week extension. There was a significant reduction in percentage time in hypoglycemia (<3.0 mmol/L) in the group switching from flash to RT-CGM (from 5.0 [3.7-8.6]% to 0.8 [0.4-1.9]%, P = 0.0001), whereas no change was observed in the RT-CGM group continuing with the additional 8 weeks of RT-CGM (1.3 [0.4-2.8] vs. 1.3 [0.8-2.5], P = 0.82). Time in target (3.9-10 mmol/L) increased in the flash group after switching to RT-CGM (60.0 [54.5-67.8] vs. 67.4 [56.3-72.4], P = 0.02) and remained the same in the RT-CGM group that continued with RT-CGM (65.9 [54.1-74.8] vs. 64.9 [49.2-73.9], P = 0.64). CONCLUSIONS: Our data suggest that switching from flash to RT-CGM has a significant beneficial impact on hypoglycemia outcomes and that continued use of RT-CGM maintains hypoglycemia risk benefit in this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Increased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
the SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway
Skrivarhaug, T., Bangstad, H.-J., Stene, L. C., Sandvik, L., Hanssen, K. F., & Joner, G. (2006) · Diabetologia · doi:10.1007/s00125-005-0082-6 · Cited by 390
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Reddy, M., Jugnee, N., El Laboudi, A., Spanudakis, E., Anantharaja, S., & Oliver, N. (2018) · Diabetic Medicine · doi:10.1111/dme.13561 · Cited by 245 · cited 1×
“The details of study visits for the first 8-week intervention period have been published.(18) Those participants who decided to participate in the 8-week extension phase using RT-CGM (Dexcom G5), using either the G5 receiver or the G5 app on their smartphone, entered this phase immediately after completing the first 8…”
MethodSelf-citation
Cited by
The relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Visser, M. M., Charleer, S., Fieuws, S., De Block, C., Hilbrands, R., Van Huffel, L., Maes, T., Vanhaverbeke, G., Dirinck, E., Myngheer, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00789-3 · Cited by 165
Tyndall, V., Stimson, R. H., Zammitt, N. N., Ritchie, S. A., McKnight, J. A., Dover, A. R., & Gibb, F. W. (2019) · Diabetologia · doi:10.1007/s00125-019-4894-1 · Cited by 165
“The only head-to-head comparison of flash monitoring and CGM in IAH did, however, suggest benefit only with the latter technology, suggesting real-time alarms may be essential in this group [18].”
BackgroundHásková, A., Radovnická, L., Petruželková, L., Parkin, C. G., Grunberger, G., Horová, E., Navrátilová, V., Kádě, O., Matoulek, M., Prázný, M., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0112 · Cited by 146
Metadata
- Authors
- Reddy, M., Jugnee, N., Anantharaja, S., & Oliver, N.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-11
- Volume
- 20
- Issue
- 11
- Pages
- 751-757
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2893605911
- Cited by
- 91
- References
- 10
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.